Lyell Immunopharma, Inc.(LYEL)Earnings, Financials & Key RatiosLyell Immunopharma, Inc. (LYEL) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's cash position of $90.8 million in 2026Q1, when measured against consistent quarterly operating losses, suggests a high risk of near-term capital depletion and shareholder dilution.
Lyell Immunopharma, Inc. (LYEL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Lyell Immunopharma, Inc. (LYEL) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $1.10vs $2.78+60.4% | $2,000vs $3,000-33.3% |
| Q2 2026 | Mar 12, 2026 | $7.68vs $2.15-257.2% | $6,000vs $15,250-60.7% |
| Q4 2025 | Nov 12, 2025 | $2.13vs $2.81+24.2% | $15,000 |
| Q3 2025 | Aug 12, 2025 | $2.89vs $3.80+23.9% | $8,000vs $4,000+100.0% |
Recent stock market news and headlines for Lyell Immunopharma, Inc. (LYEL)
The average of price targets set by Wall Street analysts indicates a potential upside of 176% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in a fireside chat at the H.C.
Key metrics vs top competitors for Lyell Immunopharma, Inc. (LYEL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.91 | $371.25M | -0.99 | -40.98% | -762355.56% | -86.98% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $1.35 | $171.71M | -1.21 | 14.85% | -173.02% | — | — | |
| $3.10 | $505.47M | -1.89 | — | — | -131.58% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — |
Lyell Immunopharma, Inc. (LYEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Lyell Immunopharma, Inc. (LYEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 6, 2026·SEC
Mar 12, 2026·SEC
Mar 9, 2026·SEC
Get notified when LYEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Lyell Immunopharma, Inc. (LYEL) stock FAQ — growth, dividends, profitability & financials explained
Lyell Immunopharma, Inc. (LYEL) reported $0.0M in revenue for fiscal year 2025. This represents a 95% decrease from $0.7M in 2019.
Lyell Immunopharma, Inc. (LYEL) saw revenue decline by 41.0% over the past year.
Lyell Immunopharma, Inc. (LYEL) reported a net loss of $246.4M for fiscal year 2025.
Lyell Immunopharma, Inc. (LYEL) has a return on equity (ROE) of -87.0%. Negative ROE indicates the company is unprofitable.
Lyell Immunopharma, Inc. (LYEL) had negative free cash flow of $134.4M in fiscal year 2025, likely due to heavy capital investments.
